Abstract:Abstract Background The identification of exploitable molecular pathogeneses for Alzheimer’s (AD) is an ongoing neurotherapeutic priority, yielding a range of different mechanistic proposals including proteopathy, immunopathy, gliopathy, synaptopathy, mitochondriopathy, oxidative stress, and metal dyshomeostasis. Rather than unconditionally accepting/rejecting the role of any one specific disease mechanism, the need for an innovative broadly‐encompassing model of AD, which harmonizes multiple divergent theories into a single unified comprehensive explanation, emerges as a much‐needed milestone on the road to a cure. Characterizing AD as a neurotoxic autoimmune‐inflammatory disorder, culminating in concurrent, interdependent immunopathic and proteopathic pathogeneses, may be such a milestone. Method We performed a comprehensive series of in silico, in vitro and in vivo studies explicitly evaluating the atomistic‐molecular mechanisms of cytokine‐mediated and Aβ‐mediated neurotoxicities in AD. Next, 981 new chemical entities were designed and synthesized to probe the biochemical pathways identified by these molecular mechanism studies and to provide prototypic starting points in the development of small molecule therapeutics for AD. Result In response to various stimuli (infection, trauma, ischemia, air pollution), Aβ is released as an early responder immunopeptide triggering an innate immunity cascade in which Aβ exhibits both immunomodulatory and antimicrobial properties (whether bacteria are present, or not), resulting in a misdirected attack upon ‘self’ neurons, arising from analogous electronegative surface topologies between neurons and bacteria, and rendering them similarly susceptible to membrane‐penetrating attack by antimicrobial peptides such as Aβ. Following this self‐attack, the resulting necrotic neuronal breakdown products diffuse to adjacent neurons eliciting further release of Aβ, leading to a chronic self‐perpetuating autoimmune cycle. AD thus emerges as a brain‐centric autoimmune disorder of innate immunity. Since autoimmune processes are susceptible to endogenous regulatory processes, a subsequent comprehensive screening program of 1,137 small molecules normally present in human brain identified tryptophan and arginine metabolism as regulators of brain innate immunity and a source of endogenous anti‐Alzheimer’s molecules capable of modification into therapeutic modulators targeting AD’s complex immunopathic‐proteopathic pathogenesis. Conclusion Conceptualizing AD as an autoimmune disease, identifying endogenous regulators of this autoimmunity, and designing small molecule drug‐like analogues of these endogenous regulators represents a novel therapeutic approach for AD.

Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses

Neuroinflammation induced by amyloid-forming pancreatic amylin: Rationale for a mechanistic hypothesis

Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites

Alzheimer’s Disease as an Innate Autoimmune Disease Regulated by Tryptophan and Arginine Metabolism

Immune attack: the role of inflammation in Alzheimer disease

Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease

Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β

Insulin Signaling in Sporadic Alzheimer's Disease.

Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease.

Nucleic Acid-Containing Amyloid Fibrils Potently Induce Type I Interferon and Stimulate Systemic Autoimmunity

Inflammation-Dependent Cerebral Deposition of Serum Amyloid A Protein in A Mouse Model of Amyloidosis

Involvement of inflammation in Alzheimer’s disease pathogenesis and therapeutic potential of anti-inflammatory agents

β-Amyloids and Immune Responses Associated with Alzheimer's Disease

Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses

Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?

Elevated amyloidoses of human IAPP and amyloid beta by lipopolysaccharide and their mitigation by carbon quantum dots

How our bodies fight amyloidosis: effects of physiological factors on pathogenic aggregation of amyloidogenic proteins

Short Amyloid-Beta Immunogens Show Strong Immunogenicity and Avoid Stimulating Pro-Inflammatory Pathways in Bone Marrow-Derived Dendritic Cells from C57BL/6J Mice in Vitro

A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses

Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis

NOVEL AMYLOID-β OLIGOMER-SPECIFIC EPITOPES: A HYPOTHESIS DRIVEN APPROACH TO ALZHEIMER'S IMMUNOTHERAPEUTICS